Comparative Pharmacology
Head-to-head clinical analysis: CINOXACIN versus OFLOXACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CINOXACIN versus OFLOXACIN.
CINOXACIN vs OFLOXACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II), blocking DNA replication and transcription.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
1 g orally twice daily for 7-14 days.
400 mg orally or intravenously every 12 hours for 7-14 days; for uncomplicated gonorrhea, 400 mg as a single oral dose.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours in healthy adults. Prolonged in renal impairment (up to 20-30 hours in anuria).
Clinical Note
moderateCiprofloxacin + Digoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateOfloxacin + Digoxin
"Ofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateLevofloxacin + Digoxin
"Levofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCinoxacin + Digoxin
"Cinoxacin may decrease the cardiotoxic activities of Digoxin."
Terminal elimination half-life is 4-8 hours in adults with normal renal function; prolonged to 20-50 hours in severe renal impairment (CrCl <20 mL/min).
Primarily renal excretion as unchanged drug (approximately 60-70%) and as glucuronide conjugates (approximately 20-30%). Biliary/fecal excretion accounts for less than 5%.
Approximately 70-90% of an oral dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 4-8% is excreted in feces as unchanged drug and metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic